DexCom, Inc. DXCM
86.62
(0.85)
(0.97%)
as of 25 Sep
- Market cap
- $33.0B
- P/E
- 33.4×
Follow DXCM
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
DexCom, Inc. (DXCM) Shares outstanding
DexCom, Inc.'s shares outstanding at the end of fiscal 2025 was $405.5M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $390.1M. Over the past ten years it has ranged from $319.2M (fiscal 2015) to $428.8M (fiscal 2021); the current reading is higher than 55% of that period. DexCom, Inc. ranks 10th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $405.5M | (1.74%) |
| FY2024 | $412.7M | (3.01%) |
| FY2023 | $425.5M | (0.47%) |
| FY2022 | $427.5M | (0.30%) |
| FY2021 | $428.8M | 2.00% |
| FY2020 | $420.4M | 13.87% |
| FY2019 | $369.2M | 4.65% |
| FY2018 | $352.8M | 2.20% |
| FY2017 | $345.2M | 3.23% |
| FY2016 | $334.4M | 4.76% |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $390.1M | (0.89%) |
| Mar 2026 | $393.6M | (2.93%) |
| Dec 2025 | $405.5M | (0.47%) |
| Sep 2025 | $407.4M | (0.20%) |
| 42 more quarters | Free account |
Against its own ten years
Low $319.2M
High $428.8M
Ten-year median
$405.5M
Current reading's percentile
55
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| BSX Boston Scientific Corporation compare | $1.5B |
| PHG Koninklijke Philips N.V. compare | $968.6M |
| EW Edwards Lifesciences Corporation compare | $577.6M |
| GEHC GE HealthCare Technologies Inc. compare | $454.0M |
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| DXCM DexCom, Inc. | $390.1M |
| ZBH Zimmer Biomet Holdings, Inc. compare | $192.8M |
| STE STERIS plc compare | $97.9M |
| PEN Penumbra, Inc. compare | $39.6M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on DXCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement